Business Results
First Three Months of the Fiscal Year Ending March 31, 2027

Sysmex Corporation
August 7, 2026

Together for a better healthcare journey

Disclaimer

- This material contains forward-looking statements about the Sysmex Group. These forward-looking statements are based on the current judgments and assumptions of the Sysmex Group in light of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future course of our business operations and changes in operating environments both in Japan and overseas may cause our actual results, performance, achievements, or financial position to be materially different from any future results, performance, achievements or financial position either expressed or implied within these forward-looking statements.

- The information on products and other matters contained herein is not intended as advertising or medical advice, whether or not regulatory approval has been obtained.

- The Sysmex Group adopted International Financial Reporting Standards (IFRS) in the fiscal year ended March 31, 2017. Figures are disclosed in compliance with IFRS.

Index

1. Executive Summary

Executive Summary
(First Three Months of the Fiscal Year Ending March 31, 2027: Year on Year)

sysmex

Strong growth in the Americas and yen depreciation drove substantial increases in sales and profits.

Net sales	Operating profit	Profit attributable to owners of the parent
¥130.6 billion **+23.6%** YoY	**¥14.8** billion **+39.5 %** YoY	**¥8.6** billion **+90.9%** YoY

Forex impact* Year-on-year change excluding foreign exchange effects is shown in parentheses.

Net sales: +¥11.61 billion (+12.6%); SG&A expenses: +¥3.32 billion (+2.6%); operating profit: ¥+0.46 billion (+35.1%)

Key reasons for higher sales

- ✓ Significant growth in the hematology field, centered on the Americas
- ✓ Solid growth in the EMEA and AP regions, helped by the impact of yen depreciation

(On a local currency basis)

■ Americas +26.1% / EMEA +11.0% / AP +7.6%*

*Year-on-year change on a yen basis, excluding the impact of exchange rate fluctuations

■ China - 33.8%, in line with initial forecast

Key reasons for higher profits

- ✓ Higher gross profit resulting from increased sales, together with the elimination of one-time factors from the previous fiscal year (inventory revaluation) contributed to the increase in profit.

Cash generation* Year-on-year change is shown in parentheses.

- ✓ Cash flows from operating activities: ¥35.5 billion (+ ¥26.1 billion)
- ✓ Free cash flow: ¥17.0 billion (+ ¥19.6 billion)

Executive Summary
(Revised First-Half and Full-Year Forecasts for the Fiscal Year Ending March 31, 2027)

**We revised our first-half forecast upward in light of strong business progress in the Americas.
For the second half, we have maintained our initial forecast.**

First-half forecast (revised)

Net sales	Operating profit	Profit attributable to owners of the parent
¥265.0 billion	**¥25.0** billion	**¥15.0** billion
vs. initial forecast: **+¥10.0 billion**	vs. initial forecast: **+¥2.0 billion**	vs. initial forecast: **+¥1.0 billion**
YoY: **+14.0%**	YoY: **-24.1%**	YoY: **-21.1%**

- ✓ In addition to strong business progress in the Americas, the positive impact of yen depreciation in Q1 is contributing to results.
- ✓ The forecast includes the possibility of one-time expenses in the Q2 related to business reviews and other factors.

Full-year forecast (revised)

Net sales	Operating profit	Profit attributable to owners of the parent
¥545.0 billion	**¥60.0** billion	**¥37.0** billion
vs. initial forecast: **+¥10.0 billion**	vs. initial forecast: **+¥2.0 billion**	vs. initial forecast: **+¥1.0 billion**
YoY: **+9.0%**	YoY: **+15.8%**	YoY: **+4.4%**

- ✓ The initial forecast for the second half remains unchanged.
  - The forecast may be revised, if necessary, once the impact of new regulation in China and the business portfolio review becomes clearer.

2. Business Results, First Three Months of the Fiscal Year Ending March 31, 2027

Financial Highlights (Year on Year)

(Billions of yen)

(Billions of yen)	First three months of fiscal year ending March 31, 2027		First three months of fiscal year ended March 31, 2026		YoY (Previous period = 100%)
	Results	Ratio	Results	Ratio	
Net sales	130.6	100%	105.7	100%	123.6%
Cost of sales	64.3	49.3%	51.2	48.5%	125.5%
SG&A expenses	42.6	32.6%	38.2	36.2%	111.3%
R&D expenses	7.2	5.5%	6.4	6.1%	112.5%
Other income (expenses)	(1.6)	-	0.8	0.8%	-
Operating profit	14.8	11.3%	10.6	10.1%	139.5%
Profit attributable to owners of the parent	8.6	6.7%	4.5	4.3%	190.9%



	Q1 of fiscal year ending March 31, 2027	Q1 of fiscal year ended March 31, 2026
1USD	¥159.3	¥144.6
1EUR	¥185.3	¥163.8
1CNY	¥23.4	¥20.0

Breakdown of Net Sales (By Business and Field)

Sales by Business and Field



(Billions of yen)

	First three months of fiscal year ending March 31, 2027		YoY (Previous period = 100%)		
	Results	**Ratio**	Yen basis	Excluding FX impact	Excluding China and FX impacts
Net sales	**130.6**	**100.0%**	**123.6%**	**112.6%**	**121.6%**
Hematology	**80.2**	**61.4%**	**123.8%**	**112.1%**	**115.5%**
FCM	**1.5**	**1.2%**	**251.4%**	**225.5%**	**180.7%**
Urinalysis	**11.0**	**8.5%**	**113.6%**	**102.2%**	**107.4%**
Hemostasis	**14.6**	**11.2%**	**99.5%**	**90.9%**	**138.0%**
Immunochemistry	**5.2**	**4.0%**	**129.8%**	**121.5%**	**165.3%**
Clinical chemistry	**3.8**	**2.9%**	**596.1%**	**591.9%**	**678.2%**
Life science	**6.5**	**5.1%**	**129.1%**	**118.4%**	**117.8%**
Others	**6.6**	**5.0%**	**127.3%**	**116.2%**	**116.3%**
Diagnostics business	**129.7**	**99.3%**	**123.8%**	**112.7%**	**121.8%**
Medical robotics business	**0.9**	**0.7%**	**102.9%**	**102.7%**	**103.3%**

Breakdown of Net Sales (By Destination and Product Type)

sysmex

Substantial increase in net sales, driven by growth in the Americas, EMEA, AP, and Japan, together with the positive impact of yen depreciation

(Billions of yen)	First three months of fiscal year ending March 31, 2027 Results	Ratio	YoY (Previous period = 100%) Yen basis	Local currency basis
Net sales	130.6	100.0%	123.6%	112.6%*
Americas	41.9	32.1%	138.9%	126.1%
EMEA	44.1	33.8%	125.5%	111.0%
China	13.3	10.2%	77.5%	66.2%
AP	13.8	10.6%	114.2%	107.6%*
Japan	17.3	13.3%	157.9%	-
Instruments	29.4	22.5%	151.6%	138.2%*
Reagents	75.9	58.1%	113.7%	103.2%*
Services	18.1	13.9%	116.2%	105.9%*
Others	7.2	5.5%	82.1%	171.7%*

*Year-on-year change on a yen basis, excluding the impact of exchange rate fluctuations

Major Reasons for Changes by Destination Note: On a local currency basis

Americas	• Favorable business performance continued, centered on North America and Brazil. **Sales increased substantially**, with growth across the hematology, hemostasis, and immunochemistry fields.
EMEA	• Double-digit growth in major countries drove solid expansion across key fields, including hematology, hemostasis, and urinalysis, resulting **in higher sales**.
China	• **Sales declined** due to the continuing impact of healthcare cost control policies that became apparent from Q2 of the previous fiscal year and distributor inventory adjustments. Results remained in line with the initial forecast.
AP	• In addition to strong growth in India, a recovery in Indonesia contributed to **higher sales**.
Japan	• Sales of both instruments and reagents returned to usual levels. The clinical chemistry business we acquired in April also contributed, resulting in **a substantial increase in sales**.

By Destination

(Billions of yen)



(First three months of years to March 31)

By Product Type

(Billions of yen)



(First three months of years to March 31)

Information by Destination (Americas)

(Million USD)	First three months of fiscal year ending March 31, 2027	First three months of fiscal year ended March 31, 2026	YoY (Previous period = 100%) Local currency basis	Yen basis
Net sales	**263.3**	208.9	**126.1%**	138.9%
Instruments	**80.8**	41.5	**194.7%**	214.6%
Reagents	**115.4**	106.6	**108.3%**	119.3%
Services, others	**67.0**	60.7	**110.4%**	121.7%



Favorable business performance continued, centered on North America and Brazil. **Sales increased substantially**, with growth across the hematology, hemostasis, and immunochemistry fields.

Instruments

- ✓ Sales increased significantly, led by strong performance in the hematology and hemostasis fields, particularly in North America.
- ✓ In the hematology field, progress in installing XN™-Series units ordered in North America drove sales growth.

Reagents

- ✓ Sales increased across all fields, supported by growth in the installed base of instruments, particularly in the hematology, urinalysis, and hemostasis fields.
- ✓ Sales of amyloid β testing reagents also remained strong. (Sales: USD 2.3 million)

Information by Destination (EMEA)

(Million EUR)	First three months of fiscal year ending March 31, 2027	First three months of fiscal year ended March 31, 2026	YoY (Previous period = 100%) Local currency basis	Yen basis
Net sales	**238.1**	214.6	**111.0%**	125.5%
Instruments	**57.5**	47.2	**121.9%**	137.9%
Reagents	**144.6**	134.4	**107.6%**	121.7%
Services, others	**35.8**	32.9	**108.8%**	123.3%

Sales (Million EUR)



(First three months of years to March 31)

Note: Sales in Russia have been excluded, including for past years.

Double-digit growth in major countries drove solid expansion across key fields, including hematology, hemostasis, and urinalysis, resulting in **higher sales**.

Instruments

- ✓ Sales of the XR™-Series grew in France and Austria, and performance in the urinalysis field was favorable in Germany and Italy.
- ✓ In the hemostasis field, sales increased steadily across countries, centered on Germany and Italy.

Reagents

- ✓ Sales increased, driven by growth in the installed base of instruments in major fields, including hematology.
- ✓ In the hemostasis field, sales also increased in Germany, where we won major tenders in the previous fiscal year, as well as in Saudi Arabia and other countries.

Information by Destination (China)

(Million CNY)	First three months of fiscal year ending March 31, 2027	First three months of fiscal year ended March 31, 2026	YoY (Previous period = 100%)	
			Local currency basis	Yen basis
Net sales	**571.6**	864.0	**66.2%**	77.5%
Instruments	**33.9**	87.6	**38.8%**	45.4%
Reagents	**474.5**	702.9	**67.5%**	79.1%
Services, others	**63.0**	73.3	**85.9%**	100.7%



Sales declined due to the continuing impact of healthcare cost control policies that became apparent from Q2 of the previous fiscal year and distributor inventory adjustments.

- **Instruments**
  - ✓ Sales declined as distributors continued to adjust inventories amid growing concerns over the expansion of healthcare cost control policies.
- **Reagents**
  - ✓ Sales declined, mainly in the hemostasis field, due to the impact of the principle of minimal necessity.
  - ✓ Sales declined, as distributors continued to adjust inventories, particularly in the hematology field.
  - ✓ The impact of the standardization of testing prices has not yet become apparent.

China: Current Situation and Outlook for the Future

Q1 results remained inline with initial forecast and we maintained our initial full-year forecast

YoY Change in Sales (Previous period = 100%)(Conceptual) (pt)



Q1 Results for the Fiscal Year Ending March 31, 2027: As Expected

- The impacts of the principle of minimal necessity and distributor inventory adjustments continued.

Outlook for the Fiscal Year Ending March 31, 2027

1H: We expect Q2 performance to also remain within the range assumed in the initial forecast.

2H: We expect the principle of minimal necessity to run its course
There is a risk that distributor inventory adjustments may continue (instruments).
The impact of the standardization of testing prices is expected to expand nationwide from Q4, but the situation remains uncertain.

We will closely monitor developments and disclose any significant changes in a timely manner.

Second Round of Public Consultation on the Standardization of Testing Prices


国家医疗保障局司便函

检验类医疗服务价格项目立项指南
再次征求意见函

各省、自治区、直辖市及新疆生产建设兵团医疗保障局：

为规范管理医疗服务价格项目，使医疗服务价格项目更好计价、更好执行、更好评价、更能适应临床诊疗和价格管理需要，我司充分吸收前期反馈意见建议，修改形成了检验类医疗服务价格项目立项指南。现再次印送你单位征求意见，请结合实际研究提出意见建议，并推荐近年来获批上市、满足临床重大疾病诊断需求的高质量检验项目（含本地区已立项且有必要上升为全国统一立项的价格项目），推荐项目数量控制在5项以内，我们将统筹研究。请于7月8日17:00前反馈意见。

感谢对我们工作的大力支持！

反馈邮箱：jcs_jzc@nhsa.gov.cn

附件：检验类医疗服务价格项目立项指南（再次征求意

■ June 30 announcement (first round closed at the endo of March)

- Additional public consultation on testing parameters and pricing
- Soliciting feedback from hospitals, companies, industry associations, and other stakeholders

■ Comment submission deadline of July 6

- Approximately 50 proposed additions and revisions in total

■ Outlook

July–August	End of August	September–December
Pilot implementation in six provinces across four regions	Publication of the final version and implementation details	Nationwide rollout period

- **Testing prices are not expected to be standardized nationwide at a single minimum price.** Rather, pricing is expected to be determined by each province, taking regional characteristics and developments in the pilot provinces into account.
- Following publication of the final version, reagent prices are expected to decline. However, pricing levels have not yet been disclosed, and the impact on the Company’s business performance remains uncertain.

Information by Destination (AP)

(Billions of yen)	First three months of fiscal year ending March 31, 2027	First three months of fiscal year ended March 31, 2026	YoY(Previous period = 100%) Yen basis
Net sales	**13.8**	12.0	**114.2% (107.6%)**
Diagnostics business	**13.7**	12.0	**114.2%**
Instruments	**1.7**	2.3	**74.9%**
Reagents	**11.0**	8.6	**127.7%**
Services, others	**0.9**	1.0	**90.2%**
Medical robotics business	**0.03**	0.04	**92.0%**

Note: Figures in parentheses exclude the impact of exchange rate fluctuations.



In addition to strong growth in India, a recovery in Indonesia contributed to **higher sales**.

Diagnostics business

- **Instruments**
  - ✓ Sales declined due to delays in tender awards in India and the Philippines, among other factors.
- **Reagents**
  - ✓ In India, sales increased substantially, driven by growth in the installed base of instruments in the hematology, urinalysis, and hemostasis fields.
  - ✓ Sales were favorable, particularly in Southeast Asia, including Singapore and Malaysia, resulting in higher sales across all fields.

Medical robotics business

- ✓ Obtained marketing approval in Vietnam.

Information by Destination (Japan)

(Billions of yen)	First three months of fiscal year ending March 31, 2027	First three months of fiscal year ended March 31, 2026	YoY(Previous period = 100%) Yen basis
Net sales	**17.3**	11.0	**157.9%**
Diagnostics business	**16.4**	10.1	**162.6%**
Instruments	**3.0**	1.5	**194.8%**
Reagents	**8.5**	6.6	**129.0%**
Services, others	**4.9**	1.9	**249.6%**
Medical robotics business	**0.8**	0.8	**103.4%**

Sales (Billion JPY)



Sales of both instruments and reagents returned to typical levels. The clinical chemistry business we acquired in April also contributed, resulting in **a substantial increase in sales**

Diagnostics business

- **Instruments**
  - ✓ Sales declined in the hematology field after replacement demand ran its course.
- **Reagents**
  - ✓ Sales increased as the number of tests grew, supported by an expanded installed base of instruments in the urinalysis, hemostasis, and immunochemistry fields.
  - ✓ The temporary decrease in the previous years due to system transition eased off.
- **Business acquisition**
  - ✓ Operations started in April, contributing to sales growth in the clinical chemistry and immunochemistry fields.

Medical robotics business

- Installations during the first quarter: 2 units (cumulative installed base: 108 units)

Breakdown of Operating Profit (Year on Year)

Operating profit



Note: Figures and comments below exclude the impact of exchange rates.

- Increase in gross profit due to higher sales: +¥6.86 billion
- Absence of the prior-year impact of inventory revaluation: +¥1.75 billion
- Change in the cost of sales ratio: -¥0.71 billion (0.5pt deterioration)
  - ✓ Positive factor: Higher sales of high-margin instruments, 1.6 pt
  - ✓ Negative factors: Product mix, 3.2 pt, Tariff impact, 0.2 pt
- Increase in SG&A expenses: -¥0.99 billion
  - ✓ Personnel expenses: -¥0.5 billion due to workforce expansion associated with the expansion of direct sales regions and higher unit labor costs
- Increase in R&D expenses: -¥0.8 billion
  - ✓ Expanded investment in product development
- Change in other operating income and expenses: -¥2.38 billion
  - ✓ A provision was recorded for potential losses associated with contractual obligations

- FX impact: +¥0.46 billion

3. Strategic Themes under the Mid-Term Management Plan

Progress on Strategic Themes

Accelerate Expansion in the Hemostasis

EMEA

Q1 results (local currency basis), YoY: +41%

- Activities built on the existing hematology customer base are bearing fruit, with growth in both instruments and reagents.
- We are strengthening competitiveness through measures such as obtaining regulatory approval for special-assay reagents, including HIT IgG reagents.

Americas

Q1 results (local currency basis), YoY: +134%

- North America: Started installation of the CN™-Series. We will strengthen sales activities to secure large-scale projects going forward.
- Central and South America: We have obtained regulatory approval for the CN-Series in Brazil. Sales are scheduled to begin in Q2 of the fiscal year ending March 31, 2027.

Expansion in Emerging Markets

Sales (Q1)

Emerging Markets (Asia, Central and South America, Middle East, Africa)



Steady growth in each region



Developing new products to meet Indian market demand



Favorable growth in the hematology and urinalysis fields

Progress on Initiatives to Improve Profitability

Value Chain Reform

Improving Reagent Profitability

- A Company-wide project is underway to improve reagent costs and accelerate initiatives to enhance profitability.

Key initiatives:

Hematology field

- Reviewing raw materials and manufacturing processes for reagents such as staining and hemolysis reagents, and promoting optimization initiatives

→Although the gross margin is already high and the scope for improvement is limited, meaningful benefits are expected given the scale of the business.

Immunochemistry field

- Promoting reductions in production frequency and the in-house production of raw materials, centered on infectious disease testing parameters such as HBV and HCV, through production scale-up

→Although the scale of the business is limited, reagent costs are higher than in other fields, leaving substantial room for improvement.

Improving Productivity through AI and Digital Technologies

Internal data × AI · Digital = A High-productivity corporate structure

- Leveraging globally accumulated operational data to drive business transformation aimed at improving profitability and efficiency.



✓ Detailed analysis of order receipt, shipment, invoicing, and payment processes

✓ Identified factors behind extended shipment lead times and manual operations

Transition to the execution phase

✓ Shortening lead time from order receipt to shipment

✓ Initiated standardization and automation of customer order processing

We will improve profitability and capital efficiency through the twin pillars of value chain reform and utilizing digital technologies

4. Financial Forecast for the Fiscal Year Ending March 31, 2027

Revised Financial Forecast for the Fiscal Year Ending March 31, 2027 (First Half)

Green indicates changes from the previous forecast (announced in May 2026).

(Billions of yen)	Q1 of fiscal year ending March 31, 2027 (April–June)		Q2 of fiscal year ending March 31, 2027 (July–September)		Announced forecast for first six months of fiscal year ending March 31, 2027 (April – September)			
	Results	Ratio	Forecast	Ratio	revised	Ratio	YoY (Previous period = 100%)	vs. initial forecast
Net sales	130.6	100%	134.3	100%	265.0	100.0%	114.0%	+10.0
Cost of sales	64.3	49.3%	64.6	48.1%	129.0	48.7%	117.3%	+2.0
SG&A expenses	42.6	32.6%	47.4	35.3%	90.0	34.0%	115.6%	±0.0
R&D expenses	7.2	5.5%	7.8	5.8%	15.0	5.7%	113.6%	±0.0
Other income (expenses)	(1.6)	-	(4.3)	-	(6.0)	-	-	(6.0)
Operating profit	14.8	11.3%	10.2	7.6%	25.0	9.4%	75.9%	+2.0
Profit attributable to owners of the parent	8.6	6.7%	6.3	4.7%	15.0	5.7%	78.9%	+1.0

Exchange Rates (Actual/Assumed)	Q1 of fiscal year ending March 31, 2027 (April–June) (Results)	Q2 of fiscal year ending March 31, 2027 (July–September) (Unchanged)	1H (Revised August 2026)
1 USD	¥159.3	¥155.0	¥157.2
1 EUR	¥185.3	¥180.0	¥182.6
1 CNY	¥23.4	¥22.0	¥22.7

Revised Financial Forecast for the First Half of the Fiscal Year Ending March 31, 2027

Net Sales

(Billions of yen)



Operating Profit

(Billions of yen)



Revised Financial Forecast for the Fiscal Year Ending March 31, 2027 (Full Year)

Green indicates changes from the previous forecast (announced in May 2026).

(Billions of yen)	2H of fiscal year ending March 31, 2027 (October–March)		Full-year forecast for fiscal year ending March 31, 2027 (April–March)			
	Forecast	Ratio	revised	Ratio	Year on year	vs. initial forecast
Net sales	280.0	100%	545.0	100.0%	109.0%	+10.0
Cost of sales	140.0	50.0%	269.0	49.4%	110.1%	+2.0
SG&A expenses	91.0	32.5%	181.0	33.2%	110.1%	±0.0
R&D expenses	15.0	5.4%	30.0	5.5%	102.9%	±0.0
Other income (expenses)	1.0	0.4%	(5.0)	-	-	(6.0)
Operating profit	35.0	12.5%	60.0	11.0%	115.8%	+2.0
Profit attributable to owners of the parent	22.0	7.9%	37.0	6.8%	104.4%	+1.0

	Full-year forecast
ROE	7.5%
ROIC	7.5%
CCC	200 days
Operating cash flow	¥89.0 billion
Free cash flow	¥28.0 billion

- **Assumed Exchange Rates**

	1H (Revised Aug. 2026)	2H (Unchanged)	Full year (Revised Aug. 2026)
1 USD	¥157.2	¥155.0	¥156.1
1 EUR	¥182.6	¥180.0	¥181.3
1 CNY	¥22.7	¥22.0	¥22.4

- **Exchange Rate Sensitivity***

	Net sales	Operating profit
USD	¥0.87 billion	¥0.22 billion
EUR	¥0.64 billion	¥0.07 billion
CNY*	¥0.33 billion	¥0.24 billion

*Impact of a ¥0.1 change in the exchange rate

Planned investment（Unchanged）：Capital expenditure ¥48.0 billion, Depreciation and amortization ¥47.0 billion

Revised Forecast for the Fiscal Year ending March 31, 2027 (Sales by Business, Field, and Destination)

■ Sales by business and field

(Billions of yen)	Fiscal year ending March 31, 2027	Ratio	YoY (Previous period = 100%)
Hematology	325.0	59.6%	108.5%
FCM	7.5	1.4%	159.9%
Urinalysis	49.0	9.0%	111.2%
Hemostasis	74.0	13.6%	102.2%
Immunochemistry	23.0	4.2%	103.1%
Clinical chemistry	13.0	2.4%	445.7%
Life science	24.0	4.4%	96.2%
Others	24.0	4.4%	92.5%
Diagnostics business	539.5	99.0%	108.6%
Medical robotics business	5.5	1.0%	166.5%
Total	545.0	100%	109.0%

■ Sales by destination

Green indicates changes from the previous forecast (announced in May 2026).

(Billions of yen)	Fiscal year ending March 31, 2027	Ratio	YoY (Previous period = 100%)	
			Yen basis	Local currency basis
Americas	158.5	29.1%	113.8%	110.1%
EMEA	176.0	32.3%	111.4%	107.6%
China	76.5	14.0%	85.5%	81.8%
AP	62.0	11.4%	113.5%	-
Japan	72.0	13.2%	122.9%	-

(Appendix)

Sustainability Targets
Results for the Fiscal Year Ended March 31, 2026

Creating value for a healthy society

・The items whose targets are displayed as "-" are monitoring items for which no targets are set.

Materiality	KPI	Results		Targets
		Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026	Fiscal year ending March 31, 2027
Improving the quality of life of each individual and extending healthy life expectancy Improving the safety and productivity of healthcare professionals Improving healthcare economics Improvement in accessibility to healthcare	Number of hematology tests	2,904 million*1	3,014 million	-
	Hematology market share*2	56.0%*1	56.1%	-
	Number of cases with surgical support robot	5,209	7,857	-
	Number of patents	3,337	2,931	-
	Number of new patents	182	173	-
	Number of patent genomes analyzed*3	1.8 thousand	1.7 thousand	-
	Number of breast cancer tests using the OSNA™ method	53 thousand	53 thousand	-
	Sales in emerging and developing markets*4	¥179.5 billion	¥157.4 billion	-

Providing responsible products, services, and solutions

Materiality	KPI	Results		Targets
		Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026	Fiscal year ending March 31, 2027
Pursuit of quality and trust	Number of recalls	6	6	-
	Number of FDA warning letters	0	0	-
Maintaining stable supply through the development of a resilient supply chain	CSR survey response rate (primary suppliers in Japan and overseas)	95%	95%	90%
	Number of training sessions for suppliers (Japan)*5	6	6	3
	Third-party certification rate of suppliers (primary, Japan) *5	89%	90%	-

*1 The previous year's figure has been revised, owing to a change in calculation method. *2 Source: Clearstate and Sysmex's assumptions
*3 Target: Sysmex Group in Japan *4 :including China *5 Target: Sysmex Corporation on a non-consolidated basis

Sustainability Targets
Results for the Fiscal Year Ended March 31, 2026

Reducing environmental impacts

・The items whose targets are displayed as "-" are monitoring items for which no targets are set.

Materiality	KPI	Results		Targets
		Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026	Fiscal year ending March 31, 2027
Resource circulation in product life cycle	Zero product losses	0.40%	0.18%	0.16%
	Recycling of containers and packing and utilization of environment compliance materials	62%	67%	70%
	Reduction of greenhouse gas emissions (Scope 3)*1	Cut 1%	Up 8%	Cut 7%
	Supplier engagement ratio	40%	40%	—
	Reduction of packaging and labeling materials*2	Cut 4%	Cut 25%	—
Responding to climate change Efficient use of water resources	Reduction of greenhouse gas emissions (Scopes 1, 2)*1	Cut 33%	Cut 41%	Cut 44%
	Ratio of renewable energy	72%	83%	82%
	Reduction of using energy per employee*1	Cut 7%	Cut 17%	—
	Reduction of water consumption (main reagent factories)*1	Cut 31pt	Cut 25pt	Cut 34pt
	Reduction of total waste*1	Cut 33%	Cut 41%	Cut 43%
	Ratio of product waste to sales	0.5%	0.3%	—

Scope 1: GHG emitted directly by company facilities, factories, and fleet
Scope 2: GHG emitted indirectly by the company due to energy use
Scope 3: GHG emitted throughout the value chain in relation to products and services

*1 Base year: Fiscal year ended March 31, 2023
*2 Base year: Fiscal year ended March 31, 2020

Sustainability Targets
Results for the Fiscal Year Ended March 31, 2026

Strengthening governance

・The items whose targets are displayed as "-" are monitoring items for which no targets are set.

Materiality	KPI	Results		Targets
		Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026	Fiscal year ending March 31, 2027
Business activities based on legal compliance, respect for human rights, and high ethical standards Cybersecurity measures for information systems and products	Number of meetings with investors and analysts*2	753	901	-
	Number of internal reports	17	50	-
	Number of unethical incidents	19	26	-
	Number of information security trainees*1	27,060	31,744	-
	Participation rate in disaster drills*1	89.5%	88.6%	-

*1 Target: Sysmex Group in Japan
*2 Target: Sysmex Corporation on a non-consolidated basis

Sustainability Targets　Results for the Fiscal Year Ended March 31, 2026

Maximizing human capital

・The items whose targets are displayed as "-" are monitoring items for which no targets are set.

Materiality	KPI	Results		Targets
		Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026	Fiscal year ending March 31, 2027
Talent acquisition and development	Engagement score	76%	74%	75%
	Turnover ratio	8.0%	8.0%	10% or less
	Self-turnover rate	5.6%	4.4%	—
	Return rate from parental leave*2	99%	100%	—
	Percentage of men taking childcare leave*2	77%	80%	70% or more
Promotion of diversity, equity & inclusion (DE&I)	Female managers ratio	18.7%	19.7%	21%
	Female next-generation managers ratio	34.0%	34.2%	—
	Female employees rate	41.1%	41.4%	—
	Percentage of mid-career recruitment in managerial and professional positions*2	38.6%	37.8%	—
	Male/female percentage among recruits (new graduates and mid-career)*2	Newly graduated: 43.0% Mid-career: 36.5%	Newly graduated: 37.5% Mid-career: 15.7%	—
	Percentage of women and non-Japanese nationals in management	Women: 8.3% Non-Japanese: 16.7%	Women: 12.0% Non-Japanese: 16.0%	—
	Percentage of women in management of group companies	14.8%	12.3%	—
	Salary inequality in managerial and professional positions (total compensation)*2	96.2%	95.4%	—
	Salary inequality general employees (total compensation)*2	84.7%	85.9%	—
	Percentage of employees with disabilities*1	2.69%	2.63%	2.7% or more

*1 Target: Sysmex Group in Japan
*2 Target: Sysmex Corporation on a non-consolidated basis

Sustainability Targets
Results for the Fiscal Year Ended March 31, 2026

Maximizing human capital

・The items whose targets are displayed as "-" are monitoring items for which no targets are set.

Materiality	KPI	Results		Targets
		Fiscal year ended March 31, 2025	Fiscal year ended March 31, 2026	Fiscal year ending March 31, 2027
Talent acquisition and development	Training time per employee	24.7 hours	29.5 hours	40.0 hours
	Value-added productivity (non-consolidated)*2	¥15,042	¥11,230	—
	Value-added productivity (Group)	¥21.44 million	¥19.01 million	¥21.00 million
	Human resources development investment (non-consolidated)*2	¥261 million	¥222 million	—
	Human resources development investment (Group)	¥595 million	¥607 million	—
	Participation rate in training (non-consolidated)*2	100%	100%	90% or more
	Participation rate in training (Group)	96%	97.60%	—
	Success plan effectiveness Rate*2	92.3%	100%	—
	Succession coverage rate*2	289.5%	218.2%	—
Promotion of health and occupational safety	Total annual working hours*1..	1,993 hours	1,974 hours	1,980 hours
	Percentage of days of paid leave taken*1	67.1%	76.70%	75% or more
	Lost-time injury frequency rate*1	0.83*3	0.56	Less than 0.5
	Lost work day rate*1	0.05	0.04	Less than 0.05

*1 Target: Sysmex Group in Japan
*2 Target: Sysmex Corporation on a non-consolidated basis
*3 The previous year's figure has been revised, owing to a change in calculation method

Together for a better
healthcare journey